Molecular Docking of Zingerone and Gamma-Mangostin to Inhibit MAO-B and Catechol-O-Methyltransferase (COMT) in the Treatment of Parkinson’s Disease
DOI:
https://doi.org/10.33448/rsd-v11i16.37853Keywords:
Parkinson; Zingerone; Gamma-Mangostin; Catecol-O-Metiltransferase.Abstract
Currently, there is no drug that has proven neuroprotective properties in Parkinson's disease. The best-known drug is levodopa, which acts as inhibitors of the MAO-B and COMT enzymes involved in dopamine degradation. Although levodopa is the "gold standard" of treatment, as the disease progresses, most patients develop complications from the therapy and side effects. In this sense, the combination of two abundant substances and phytotherapics as alternatives to the use of traditional medicines is approached, namely Zingerone and Gamma-Mangostin. In which they presented favorable results in molecular docking.
References
Albin, R. (08 2022). Parkinson Disease. doi:10.1093/med/9780190843014.001.0001.
Alnajjar, R., Mohamed, N., & Kawafi, N. (2021). Bicyclo [1.1. 1] Pentane as phenyl substituent in atorvastatin drug to improve physicochemical properties: drug-likeness, DFT, pharmacokinetics, docking, and molecular dynamic simulation. Journal of Molecular Structure, 1230, 129628.
Attiq, A., Jalil, J., Husain, K., & Ahmad, W. (2018). Raging the War Against Inflammation With Natural Products. Frontiers in Pharmacology, 9. doi:10.3389/fphar.2018.00976.
Aversano, L., Bernardi, M. L., Cimitile, M., Iammarino, M., & Verdone, C. (2022). Early Detection of Parkinson’s Disease using Spiral Test and Echo State Networks. 2022 International Joint Conference on Neural Networks (IJCNN), 1–8. doi:10.1109/IJCNN55064.2022.9891917.
Carbunaru, S., Eisinger, R., Ramirez-Zamora, A., Bassan, D., Cervantes-Arriaga, A., Rodríguez-Violante, M., & Martinez-Ramirez, D. (02 2018). Impulse control disorders in Parkinson’s: Sleep disorders and nondopaminergic associations. Brain and Behavior, 8, e00904. doi:10.1002/brb3.904.
Carroll, L., Morris, M., O’Connor, W., & Clifford, A. (04 2021). Community aquatic therapy for Parkinson’s disease: an international qualitative study. Disability and Rehabilitation, 44, 1–10. doi:10.1080/09638288.2021.1906959.
Chang, H.-F., & Yang, L.-L. (12 2012). Gamma-Mangostin, a Micronutrient of Mangosteen Fruit, Induces Apoptosis in Human Colon Cancer Cells. Molecules (Basel, Switzerland), 17, 8010–8021. doi:10.3390/molecules17078010.
Chau, B., Jarvis, H., Law, C.-K., & Chong, T. (09 2018). Dopamine and reward: A view from the prefrontal cortex. Behavioural Pharmacology, 29, 1. doi:10.1097/FBP.0000000000000424.
Chaudhuri, K. R., Hand, A., Obam, F., & Belsey, J. (2022). Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson’s disease. Journal of Medical Economics, 25(1), 774–782. doi:10.1080/13696998.2022.2080437.
Chen, X., Wang, Y., Wu, H., Cheng, C., & Le, W. (03 2020). Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurological Sciences, 41. doi:10.1007/s10072-020-04333-5.
Dadu, A., Satone, V. K., Kaur, R., Hashemi, S. H., Leonard, H., Iwaki, H., … Faghri, F. (2022). Identification and prediction of Parkinsontextquoterights disease subtypes and progression using machine learning in two cohorts. bioRxiv. Doi:10.1101/2022.08.04.502846.
Dissanayake, K. G. C., Liyanage, R., & Waliwita, W. A. L. C. (04 2020). A Review on Medicinal Uses of Zingiber officinale (Ginger). 10, 142–148.
Do, H. T. T., & Cho, J. (2020). Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer’s Disease, Parkinson’s Disease, and Depression with Pharmacokinetic and Safety Profiles. International Journal of Molecular Sciences, 21(17). doi:10.3390/ijms21176211.
Do, H., & Cho, J. (08 2020). Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer’s Disease, Parkinson’s Disease, and Depression with Pharmacokinetic and Safety Profiles. International Journal of Molecular Sciences, 21, 6211. doi:10.3390/ijms21176211.
Doręgowska, M., & Rudzińska-Bar, M. (01 2019). Sleep disorders in Parkinson’s disease. Wiadomosci lekarskie (Warsaw, Poland : 1960), 72, 425–431.
Fahn, S., & Poewe, W. (12 2014). Levodopa: 50 Years of a Revolutionary Drug for Parkinson Disease. Movement Disorders, 30. doi:10.1002/mds.26122.
Farfán, F., Folgueira, A., Luján, S., Fornari, A., León, M., & Valiensi, S. (09 2021). Sleep Disorders and depression in Parkinson’s Disease. Vertex (Buenos Aires, Argentina), XXXII, 13–20.
Goetz, C. G., Koller, W. C., Poewe, W., Rascol, O., Sampaio, C., Brin, M., … Tolosa, E. (07 2002). MAO-B inhibitors for the treatment of Parkinson’s disease. Movement Disorders, 17, S38–S44. doi:10.1002/mds.5559.
Hall, J. E., & Guyton, A. C. (2011). Guyton and Hall Textbook of Medical Physiology. Ανακτήθηκε από https://books.google.com.br/books?id=di5PtQAACAAJ.
Hansen, C., Miller, D., Annarumma, S., Rusch, C., Ramirez-Zamora, A., & Khoshbouei, H. (06 2022a). Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment. Journal of Neurology, 269. doi:10.1007/s00415-022-10963-w.
Hansen, C., Miller, D., Annarumma, S., Rusch, C., Ramirez-Zamora, A., & Khoshbouei, H. (06 2022b). Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment. Journal of Neurology, 269. doi:10.1007/s00415-022-10963-w.
Harro, C. C., Horak, I., Valley, K., & Wagner, D. (2022). Nordic walking training in persons with Parkinson’s disease: Individualized prescription-A case series. Physiotherapy Theory and Practice, 0(0), 1–15. doi:10.1080/09593985.2022.2063211.
Hauser, R., Li, R., Pérez, A., Ren, X., Weintraub, D., Elm, J., … Tilley, B. (11 2016). Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. Journal of Parkinson’s Disease, 7, 1–11. doi:10.3233/JPD-160965.
Hong, J., Sunwoo, M., Yoon, J., Kang, S., Sohn, Y., Lee, P., & Kim, S. (08 2020). Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson’s disease. PLOS ONE, 15, e0237472. doi:10.1371/journal.pone.0237472.
Jost, W. (08 2022). Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease. Neuropsychiatric Disease and Treatment, 18, 1603–1618. doi:10.2147/NDT.S279362.
Ju, Z., Li, M., Xu, J., Howell, D. C., Li, Z., & Chen, F.-E. (2022). Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years. Acta Pharmaceutica Sinica B, 12(6), 2790–2807. doi:10.1016/j.apsb.2022.01.002.
Juárez-Cedillo, T., González-Figueroa, E., Martinez-Rodriguez, N., Garrido-Acosta, O., & Vargas-Alarcon, G. (04 2021). Influence of COMT polymorphism in cognitive performance on dementia in community-dwelling elderly Mexican (SADEM study). doi:10.1007/s11011-021-00740-5.
Kessel, S., Frye, A., El-Gendy, A., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (01 2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nature Communications, 10. doi:10.1038/s41467-019-08294-y.
Krishnamachary, B., Subramaniam, D., Dandawate, P., Ponnurangam, S., Srinivasan, P., Ramamoorthy, P., … Anant, S. (09 2019). Targeting transcription factor TCF4 by γ-Mangostin, a natural xanthone. Oncotarget, 10, 5576–5591. doi:10.18632/oncotarget.27159.
Kuanar, D., Kabi, S., Kar, D., & Goel, R. (02 2022). Antibiotic properties of Ginger.
Kuusisto, H., Mattila, T., & Keranen, T. (09 2010). MAO-B inhibitors and dopamine agonists as initial treatment in Parkinson’s disease: a naturalistic survey. 115–115.
Käenmäki, M., Tammimäki, A., Myöhänen, T., Pakarinen, K., Amberg, C., Karayiorgou, M., … Männistö, P. (09 2010). Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. Journal of neurochemistry, 114, 1745–1755. doi:10.1111/j.1471-4159.2010.06889.x.
Lambea-Gil, Á., María-Ángeles, Requena-Calleja, & Horna-Cañete, L. (11 2021). Levodopa-Induced Dyskinesias Related to Vicia faba Ingestion in a Parkinson’s Disease Patient. Neurology India, 69, 1878. doi:10.4103/0028-3886.333436.
Lenka, A., Maria, G. D., Lamotte, G., Bahroo, L., & Jankovic, J. (2022). Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease. Expert Review of Neurotherapeutics, 22(6), 489–498. doi:10.1080/14737175.2022.2091436.
Li, J., Zhu, B.-F., Gu, Z.-Q., Zhang, H., Mei, S.-S., Ji, S.-Z., … Chan, P. (01 2022). Musculoskeletal Pain in Parkinson’s Disease. Frontiers in neurology, 12, 756538. doi:10.3389/fneur.2021.756538.
Li, Y., Pei, J., & Lai, L. (2021). Learning to design drug-like molecules in three-dimensional space using deep generative models. arXiv preprint arXiv:2104. 08474.
Liu, R., Wang, Z., Zhao, H., Qiu, S., Wang, C., Shi, X., & Lin, F. (2022). Quantitative Analysis of Lower Limb Motion in Parkinson’s Disease Based on Inertial Sensors. IEEE Sensors Journal, 1–1. doi:10.1109/JSEN.2022.3208734.
Liu, Y., Ding, L., Xianyu, Y., Nie, S., & Yang, J. (08 2022). Research on depression in Parkinson disease: A bibliometric and visual analysis of studies published during 2012–2021. Medicine, 101, e29931. doi:10.1097/MD.0000000000029931.
Lohani, S., Martig, A., Deisseroth, K., Witten, I., & Moghaddam, B. (04 2019). Dopamine Modulation of Prefrontal Cortex Activity Is Manifold and Operates at Multiple Temporal and Spatial Scales. Cell Reports, 27, 99-114.e6. doi:10.1016/j.celrep.2019.03.012.
Mahmudah, R., Adnyana, I. K., & Sukandar, E. (04 2021). Molecular docking studies of α-mangostin, γ-mangostin, and xanthone on peroxisome proliferator-activated receptor gamma diphenyl peptidase-4 enzyme, and aldose reductase enzyme as an antidiabetic drug candidate. Journal of advanced pharmaceutical technology & research, 12, 196–208. doi:10.4103/japtr.JAPTR_255_20.
Nakatani, K., Nakahata, N., Arakawa, T., Yasuda, H., & Ohizumi, Y. (02 2002). Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Biochemical pharmacology, 63, 73–79. doi:10.1016/S0006-2952(01)00810-3.
Olszewska, D., Fasano, A., Munhoz, R., Gomez, C., & Lang, A. (09 2022). Initiating dopamine agonists rather than levodopa in early Parkinson’s disease does not delay the need for deep brain stimulation. European Journal of Neurology. doi:10.1111/ene.15539.
Onyiba, C. (03 2022). A Systematic Review of Garlic and Ginger as Medicinal Spices against Viral Infections. Extensive Reviews, 2, 32–44. doi:10.21467/exr.2.1.4600.
Pigoni, A., Lazzaretti, M., Mandolini, G. M., Delvecchio, G., Altamura, A., Soares, J., & Brambilla, P. (08 2018). The impact of COMT polymorphisms on cognition in Bipolar Disorder: A review. Journal of Affective Disorders, 243. doi:10.1016/j.jad.2018.08.009.
PubChen. (2022). data deposited or computed by chemistry.
Reyes-García, L. I., Moya-Hernández, R., Rojas-Hernández, A., Flores, R., Rodríguez-Laguna, N., & Gómez-Balderas, R. (2021). Stability constants and molecular modeling of Cu (II)/AcO and Cu (II)/diclofenac complexes in ethanol. Polyhedron, 209, 115486.
Saraiva, A.A., J. Soares, Nator Costa, José Sousa, N. Ferreira, Antonio Valente, & Salviano Soares (2019). Study of Dipeptidil Peptidase 4 Inhibitors based on Molecular Docking Experiments. In Proceedings of the 12th International Joint Conference on Biomedical Engineering Systems and Technologies - Volume 3: BIOINFORMATICS, (pp. 322-330). SciTePress.
Saraiva, A.A., Soares Jeferson, Castro Miranda, Jose Sousa, N. Ferreira, J. Neto, Salviano Soares, & Antonio Valente (2020). Chikungunya Virus Inhibitor Study based on Molecular Docking Experiments. In Proceedings of the 13th International Joint Conference on Biomedical Engineering Systems and Technologies - Volume 3: BIOINFORMATICS, (pp. 200-205). SciTePres.
Shiller, D., & Lemay, M. (10 2017). Differential effects of levodopa on rapid motor plasticity in oral and upper limb movements in Parkinson’s disease. Journal of the Neurological Sciences, 381, 733–734. doi:10.1016/j.jns.2017.08.2068.
Systems, P. M. G. (2022). Molecular visualization system.
Taghavi, F., Poursasan, N., & Moosavi-Movahedi, A. (04 2021). Book: Ginger Natural Pharmacy.
Toloraia, K., Meyer, A., Beltrani, S., Fuhr, P., Lieb, R., & Gschwandtner, U. (02 2022). Anxiety, Depression, and Apathy as Predictors of Cognitive Decline in Patients With Parkinson’s Disease—A Three-Year Follow-Up Study. Frontiers in Neurology, 13. doi:10.3389/fneur.2022.792830.
Tools, M. G. L. (2022). mulecular simulation tools.
Vasileva, A., Vasilyev, V., Okushko, R. V., & Negasheva, M. A. (01 2021). Associations of catechol-O-methyl transferase gene polymorphism (COMT) with morphofunctional indicators in russian and transnistrian students. Molecular Genetics Microbiology and Virology (Russian version), 39, 42. doi:10.17116/molgen20213901142.
Verma, R., & Bisen, P. (06 2022). Ginger- A Potential Source of Therapeutic and Pharmaceutical Compounds. Journal of Food Bioactives, 18. doi:10.31665/JFB.2022.18309.
Wang, Jing, Li, D., Wang, P., Hu, X., & Chen, F. (05 2019). Ginger prevents obesity through regulation of energy metabolism and activation of browning in high-fat diet-induced obese mice. The Journal of Nutritional Biochemistry, 70. doi:10.1016/j.jnutbio.2019.05.001.
Wang, Jun, & Wang, M. (2022). The Influence of Computer Vision Algorithm on Brain Function Network Related To Parkinson’s Disease. 2022 International Conference on Artificial Intelligence in Everything (AIE), 63–67. doi:10.1109/AIE57029.2022.00020.
Yan, W., Zhao, C., Sun, L., & Tang, B. (02 2016). Association between polymorphism of COMT gene (Val158Met) with Alzheimer’s disease: An updated analysis. Journal of the Neurological Sciences, 361. doi:10.1016/j.jns.2016.01.014.
Zhang, S., Kou, X., Zhao, H., Mak, K.-K., Balijepalli, M., & Pichika, M. (01 2022). Zingiber officinale var. rubrum: Red Ginger’s Medicinal Uses. Molecules, 27, 775. doi:10.3390/molecules27030775.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Aratã Andrande Saraiva; João Paulo Oliveira da Silva; José Vigno Moura Sousa; Ayrton de Sá Brandim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
